Prasad Kulkarni on dengue monoclonal antibodies
The Lancet Infectious Diseases in conversation with - A podcast by The Lancet Group
Categories:
Prasad Kulkarni discusses a new Phase I trial in The Lancet Infectious Diseases on a dengue monoclonal antibody also known as VIS513 in healthy adults. In addition, he highlights the wider implications of this for dengue control and drug development.Read the full article:https://www.thelancet.com/journals/laninf/article/ S1473-3099(24)00030-6/fulltext?dgcid=buzzsprout_icw_podcast_generic_laninfContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://insta...
